Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disorder clinically characterised by ventricular arrhythmia, heart failure and sudden death and histologically by cardiomyocyte loss and replacement with fibrous or fibro-fatty tissue. The estimated prevalence of ARVC is 1 in 5000 of the population and it is an important cause of sudden cardiac deaths in athletes and in people under 35 years. In many individuals, the disease is caused by mutations in genes that encode different components of the intercalated disc of cardiomyocytes.
The diagnosis of ARVC is challenging due to the non-specific nature of clinical findings and the absence of a single diagnostic test. In an attempt to improve the accuracy of clinical diagnosis, a task force of international experts was convened in 1994 under the auspices of the Scientific Council of the International Society and Federation of Cardiology (ISFC) and the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Clinical and pathological features were grouped into 6 categories and assigned either major or minor status depending on the perceived specificity for the diagnosis. The presence of two major criteria from different categories, or one major and two minor, or four minor criteria, all from different categories was considered diagnostic of ARVC (1). From its inception, it was recognised that this approach had limitations, not least the lack of sensitivity of many of the criteria. This is particular true in families affected by ARVC where carriers of disease causing mutations often have very subtle findings that would not ordinarily lead to a diagnosis of ARVC in everyday clinical practice (2).
In this update, Marcus and colleagues propose modifications to the 1994 Task force criteria to increase sensitivity without losing specificity (3). The primary aims were to reduce reliance on subjective criteria for assessing ventricular structure and function and to incorporate data from cardiac magnetic resonance imaging and genetic analysis. The method was to compare data from 108 probands with newly diagnosed ARVC to those of normal subjects. Diagnostic criteria were selected after analysis of their sensitivity and specificity from receiver operator curves, with exclusion of proband test data if those data were crucial for the individual’s diagnosis, to eliminate bias.
As in the original document, the diagnosis of ARVC is based on the identification of structural, histological, ECG, arrhythmic features and a family history. The sub-categorisation into major and minor criteria is also maintained. In the new system, patients are diagnosed with “definite” ARVC if they have 2 major, 1 major plus 2 minor, or 4 minor criteria from different categories, and “borderline” ARVC with 1 major and 1 minor, or 3 minor from different categories. The introduction of the novel term “borderline” ARVC enables the clinician to inform those individuals with minor abnormalities but not definite disease that they are at risk and require regular follow up.
In the original criteria, structural abnormalities were defined as severe or mild and classified as major or minor criteria, respectively. This method relied heavily on subjective assessment of RV wall thinning and wall motion abnormalities and was thus subject to substantial inter-observer variability. The new criteria are based upon quantitative measurements of ventricular volumes and function using MRI and 2-D echo corrected for body surface area (3). The inclusion of quantitative parameters is clearly a major step forward, but there are important caveats. The authors recognise that the reference values for the normal subjects were determined from select populations and so the reference values quoted will not apply to all ethnic populations and may not apply to those under 12 years of age. Some subjectivity remains; for instance, major and minor echo criteria are defined by the presence of a regional wall motion abnormality (although hypokinesis is now excluded) which can be extremely difficult to assess using conventional 2-D echocardiography. Cardiac MRI theoretically reduces subjective bias as it not restricted by acoustic windows and can accurately assess RV wall motion abnormalities and volumes (4). However, significant degrees of inter-observer variability with regard to interpretation of wall thinning, localised functional abnormalities and fatty deposition are still a problem even with CMR (5) and so imaging should be performed in specialist centres using a dedicated protocol to analyse volumes, RV regional wall motion abnormalities and delayed enhancement imaging (6). The same is true of RV angiography, which although regarded as the gold standard imaging technique for ARVC in the past requires significant experience and should be reserved for specialised centres that frequently perform the technique (7,8).
This category previously only had one major criterion, which was met if fibrofatty replacement could be demonstrated on endomyocardial biopsy. It has now been subclassified into major and minor criteria dependent on the percentage of observed residual myocytes in an endomyocardial biopsy with observed fibrous replacement, with or without fatty replacement (3). The conventional endomyocardial biopsy however lacks sufficient sensitivity due to the segmental nature of the disease. Studies show that biopsy guided by electroanatomic voltage mapping to areas of low voltage, may increase the diagnostic accuracy of biopsy (9). A role for endomyocardial biopsy and immunohistochemical testing has emerged recently. A reduced immunoreactive signal for plakoglobin at intercalated discs was a consistent feature of ARVC and not other forms of diseases and this approach represents an exciting potential new diagnostic test for ARVC but is appropriately not included in the proposed revised criteria as it requires confirmation in larger series before being adopted as a reliable diagnostic technique (10).
ECG changes in ARVC are reported in up to 98% of cases (11). The most common repolarisation abnormality is T wave inversion in the right praecordial leads (V1-V3) in the absence of right bundle branch block (RBBB), which has been reported in 54%-85% of probands (12,13). These repolarisation abnormalities were previously considered as minor diagnostic criteria due to their lack of specificity and because T wave inversions are more likely to represent cases with severe dysfunction (14). Complete and incomplete RBBB are commonly observed in affected patients but are also common among normal subjects and were therefore excluded from the original diagnostic criteria (15). In the revised criteria T wave inversion in the right praecordial leads (V1-V3) or beyond in individuals >14 years of age in the absence of complete RBBB has been upgraded to a major criterion. Justification for this change comes from data showing that this ECG abnormality is observed in only 4% and 1% of normal women and men, respectively (15).
The new criteria also include a minor criterion for those individuals with more limited T wave inversion (V1-V2) or those with T wave inversion in the setting of complete RBBB as T wave inversion in V1-V4 in the setting of RBBB is uncommon in those who do not have ARVC and is frequently observed in those with the disease.
Depolarisation abnormalities associated with ARVC are due to the pathological changes seen in ARVC which result in delayed conduction in the RV free wall. In the original 1994 Task Force criteria, the presence of a post excitation epsilon wave (a distinct wave of small amplitude occupying the ST segment in the right precordial leads (16)) reflecting delayed right ventricular activation was considered a major diagnostic criterion (1). These have been reported in around 30% of cases (17) but the sensitivity can be significantly increased by using a highly amplified, modified recording technique. In one series, the incidence of epsilon waves increased from 23% to 77% with this change in recording technique (18) which has led to this remaining a major criterion in the proposed revised criteria (3).
Localised prolongation (>110ms) of the QRS complex in the right precordial leads (V1-V3), has been removed in the new criteria. In contrast “prolonged S wave upstroke” in V1-V3 of ≥55msec is included as a new minor criterion in the revised diagnostic criteria (17). This criterion has a high sensitivity on the standard ECG, reported in 84-95% of ARVC patients without RBBB (17,18), and has been correlated with disease severity.
The signal-averaged ECG (SAECG) is used to assess for evidence of late potentials, a sign of delayed depolarisation. This was previously considered abnormal when two or more of the following parameters were met: QRS duration >114msec; low amplitude signal duration <40μV (LAS) is >38msec or the root mean square voltage in the last 40msec of the QRS (RMS40) <20μV (19). This criterion was found to be abnormal in 58% of index cases and 45% of affected relatives (17,19). The proposed criteria now include any one of the three SAECG parameters as positive for late potentials because analysis of the sensitivity and specificity of any one criterion was similar to that of any two or three of these criteria (3).
Early studies reported ventricular arrhythmias in 42-64% of patients (19), but these did not constitute a major criterion in the original Task Force criteria. In the revised criteria, ventricular tachycardia of LBBB morphology with superior axis is reclassified as a major criterion, while LBBB VT with inferior axis is a minor criterion. This is because LBBB VT with an inferior axis is typical of RVOT tachycardia and not specific to ARVC (20).
The presence of >1000 extrasystoles in a 24 hour period was a second minor diagnostic criterion which has been reported in 22-42% (17,19). However, the cut of 1000 extrasystoles was arbitrary. The revised proposed criteria lower the volume of ventricular ectopy representing a minor criterion to >500/24 hours but again, this cut off requires further validation in prospective studies.
The original 1994 criteria defined the presence of confirmed ARVC at necropsy or surgery as a major criterion, but a family history of sudden cardiac death due to presumed ARVC or a family member meeting 1994 diagnostic criteria for the disease were only minor criteria. Since 1994, understanding of the pathophysiology of this disease has vastly expanded with the identification of numerous mutations in components of the desmosome. The revised criteria have been updated to include this genetic information.
As well as a first degree relative meeting the new Task Force criteria or a having confirmed disease at necropsy or surgery, positive genetic results in the patient under evaluation now constitute major criteria. A pathogenic mutation is categorised as associated or probably associated with ARVC if it alters or is expected to alter the encoded protein, alters or is predicted to alter the structure or function of that protein, is un-observed in large non ARVC/D control populations, or has demonstrated linkage to the disease phenotype in a conclusive pedigree. The difficulty with this criterion is that many mutations identified are novel and it can be difficult to predict the functional implication of these mutations. Minor criteria in the family history category remain a sudden cardiac death in a first-degree relative at less than 35years due to suspected ARVC or first-degree relative with a clinical diagnosis in whom the Task force criteria cannot be applied to determine if they are met or not. For the first time, a diagnosis of ARVC either clinically or pathologically in a second degree relative is also included as a minor criterion recognising that in large families where individuals are affected, small abnormalities that previously did not meet Task Force criteria could represent disease burden.
The fundamental problem with ARVC is that unlike most other cardiomyopathies, there is no simple gold standard on which to base the diagnosis. Hypertrophic and dilated cardiomyopathies, for example, are defined respectively by an increased wall thickness or ventricular dilatation with impaired systolic function, whereas the contemporary concept of ARVC is based on a triad of histopathological, clinical and genetic abnormalities that require multiple clinical and molecular tools to define them.
The aim of this new diagnostic algorithm is to enhance the definition of each of these specific components of the ARVC paradigm in order to increase the sensitivity of the previous diagnostic criteria. It is probable that this goal will be achieved with respect to patients that have right ventricular disease caused by desmosomal protein gene mutations, not least because of the prominence given to a genetic diagnosis and family history in the new scheme. However, it will also highlight the many pitfalls inherent in the techniques used to make a diagnosis. For example, assessment of right ventricular dimensions and function requires a systematic approach and a degree of experience in order to avoid misinterpretation of normal variants. Similarly, sampling error in endomyocardial biopsy can result in both false positive and false negative findings. Perhaps, the greatest danger, however, is an over reliance on genetic analysis to make a diagnosis. Emerging data are showing that some sequence variants in desmosomal protein genes are relatively common in normal controls and in patients with other cardiomyopathies. Thus, due caution should be applied when a novel sequence variant of uncertain pathogenicity is found in a patient with borderline clinical features.
It is very likely that the new criteria, if carefully and thoughtfully applied, will be more specific for the diagnosis of patients and relatives with classical right ventricular fibrofatty replacement caused by mutations in desmosomal protein genes. However, we strongly suspect that this increased specificity will probably reflect the enhanced familial and genetic criteria rather than the more detailed assessment of right ventricular size and function. The underlying assumption of the new criteria is that the histopathological, clinical and genetic concepts of the disease are highly concordant. It is important to remember, however, that in everyday clinical practice much of the information required for a “definite” diagnosis may be difficult to acquire or interpret. For example, sampling error in endomyocardial biopsy or the presence of a novel sequence variant in a desmosomal protein gene.
Moreover, the ARVC phenotype can be caused by other genetic and acquired disorders that if overlooked or misdiagnosed could result in inappropriate treatment and incorrect advice to families. In conclusion, the authors deserve praise for their thoughtful reappraisal of the 1994 criteria, but it is critically important that clinicians recognise the limitations of even the most modern diagnostic tools and always interpret the results of tests in the light of the patients presentation, family pedigree and signs and symptoms.
1. McKenna WJ, Thiene G, Nava A et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. British Heart J 1994;71:215-8
2. Hamid MS, Norman M, Quaraishi A, Firoozi S, Thaman R, Gimeno JR, Sachder B, Rowland E, Elliott PM, McKenna WJ. Prospective evaluation of relatives for familial arrhythmogenic right ventricular dysplasia/cardiomyopathy reveals a need to broaden diagnostic criteria. JACC 2002;40(8):1445-50
3. Marcus FI, McKenna WJ, Sherrill D et al. Diagnosis of Arrhythmogenic right ventricular cardiomyopathy/dysplasia. Proposed modification of the task force criteria. Circulation 2010 Feb 19 [Epub ahead of print], Eur Heart J. 2010 Feb 19 [Epub ahead of print]
4. Corrado D, Basso C, Thiene G. Arrhythmogenic right ventricular cardiomyopathy: diagnosis, prognosis and treatment. Heart 2000;83:588-95
5. Bluemke DA, Krupinski EA, Ovitt T, Gear K, Unger E, Axel L, Boxt LM, Casolo G, Ferrari VA, Funaki B, Globits S, Higgins CB, Julsrud P, Lipton N, Mauson J, Nygren A, Pennell DJ, Stillman A, White RD, Wichter T, Marcus F. Magnetic resonance imaging of arrhythmogenic right ventricular cardiomyopathy: morphological findings and inter-observer reliability. Cardiology 2003;99:153-62
6. Sen-Chowdhry S, Prasad SK, Syrris P, Wage R, Ward D, Merrifield R, Smith GC, Firmin DN, Pennell DJ, McKenna WJ. Cardiac magnetic resonance in arrhythmogenic right ventricular cardiomyopathy revisited. JACC 2006;48:2132-40
7. Indik JH, Wichter T, Gear K et al. Quantative assessment of angiographic right ventricular wall motion in Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). J Cardiovasc Electrophysiol. 2008;19:39-45
8. Wellnhofer E, Ewert P, Hug J et al. Evaluation of new software for angiographic determination of right ventricular volumes. Int J Cardiovasc Imaging. 2005;21:575-85
9. Avella A, d’Amati G, Pappalardo A, Re F, Silenzi PF, Laurenzi F, de Girolamo P, Pelargnonio G, Dello Russo A, Baratta P, Messina G, Zecchi P, Zachara E, Tondon C. Diagnostic value of endomyocardil biopsy guided by electroanatomic voltage mapping in arrhythmogenic right ventricular cardiomyopathy/dysplasia. J Cardiovasc Electrophysiol 2008;19:1127-34
10. Asimaki A, Tandri H, Huang H, Halushka M, Gautam S, Basso C, Thiene G, Tsatsopoulou A, Protonotarios N, McKenna WJ, Calkins H, Saffitz JE. A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Eng J Med 2009;360(11); 1075-84
11. Sen-Chowdhry S, Lowe MD, Sporton SC, McKenna WJ. Arrhythmogenic right ventricular cardiomyopathy: Clinical presentation, diagnosis and management. Am J Med 2004;117:685-95
12. Peters S, Trümmel M. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy: Value of standard electrocardiogram revisited. Ann Non-invas Electrocard 2003;8(3):238-45
13. Nasir K, Bommo C, Tandri H, Roquin A, Dalal D, Prakasa K, Tichnell C, James C, Tspevak P, Marcus F, Calkins H. Electrocardiographic features of arrhythmogenic right ventricular dysplasia/cardiomyopathy according to disease severity. A need to broaden diagnostic criteria. Circulation 2004;110:1527-34
14. Peters S, Trümmel M, Koehler B, Westermann KU. The value of different Electrocardiographic depolarization criteria in the diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Electrocard 2007;40:34-37
15. Marcus FI. Prevalence of T-wave inversion beyond V1 in young normal individuals and usefulness for the diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Am J Cardiol. 2005;95:1070-71
16. Fontaine G, Umemura J, di Donna P et al. Duration of QRS complexes in arrhythmogenic right ventricular dysplasia; a new non-invasive diagnostic marker. Ann Cardiol Angeiol (Paris) 1993;42:399-405
17. Nasir K, Bommo C, Tandri H, Roquin A, Dalal D, Prakasa K, Tichnell C, James C, Tspevak P, Marcus F, Calkins H. Electrocardiographic features of arrhythmogenic right ventricular dysplasia/cardiomyopathy according to disease severity. A need to broaden diagnostic criteria. Circulation 2004;110:1527-34
18. Peters S, Trümmel M, Koehler B, Westermann KU. The value of different Electrocardiographic depolarization criteria in the diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Electrocard 2007;40:34-37
19. Hamid MS, Norman M, Quaraishi A, Firoozi S, Thaman R, Gimeno JR, Sachder B, Rowland E, Elliott PM, McKenna WJ. Prospective evaluation of relatives for familial arrhythmogenic right ventricular dysplasia/cardiomyopathy reveals a need to broaden diagnostic criteria. JACC 2002;40(8):1445-50
20. Ainsworth CD, Skanes AC, Klein GJ et al. Differentiating arrhythmogenic right ventricular cardiomyopathy from right ventricular outflow tract ventricular tachycardia using multilead QRS duration and axis. Heart Rhythm 2006;3:416-423
European Society of Cardiology
Les Templiers2035 Route des CollesCS 80179 BIOT
06903Sophia Antipolis, FR